Isatuximab, Carfilzomib, and Pomalidomide for the Treatment of Relapsed or Refractory Multiple Myeloma
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04850599 |
|
Recruitment Status :
Recruiting
First Posted : April 20, 2021
Last Update Posted : June 16, 2022
|
Sponsor:
OHSU Knight Cancer Institute
Collaborators:
Oregon Health and Science University
Sanofi
Information provided by (Responsible Party):
Rebecca W. Silbermann, OHSU Knight Cancer Institute
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | April 15, 2026 |
| Estimated Study Completion Date : | February 21, 2029 |